Status:
COMPLETED
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Conditions:
Genital Herpes
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and ...
Eligibility Criteria
Inclusion
- HIV negative as determined by concordant rapid testing
- HSV-2 seropositive (Focus HerpeSelect \>3.4)
- At least one prior occurrence of GUD
- 18-50 years of age
Exclusion
- Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir
- Prior hypersensitivity \&/or allergic reaction to acyclovir
- Use of probenicid
- Current use, or use within past 28 days, of an investigational agent
- Currently pregnant or nursing
- Currently plan to become pregnant during next 3 months
- Any condition that will interfere with successful completion of study procedures
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00808405
Start Date
January 1 2009
End Date
July 1 2010
Last Update
December 11 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Reproductive Health and HIV Research Unit (RHRU)
Johannesburg, South Africa
2
Center for Infectious Disease Research of Zambia (CIDRZ)
Lusaka, Zambia